Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Chief Development Officer | August 11, 2025 | August 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date August 11, 2025 · Filed August 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 221,799 |
Reported balance
After 2025-08-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-11 · Sale · Disposed 22,073 · Balance 221,799 F1: These shares of common stock were sold in a transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards. F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.06 to $5.29. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3: Includes 7,101 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock were sold in a transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards.
F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.06 to $5.29. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Includes 7,101 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2025 Filed Aug 13, 2025 22:03 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | SaleCommon Stock | 22,073 | $5.15 | $113,713.47 |
DisclosureSEC source: 0000950170-25-108210 · ownership.xml · nonDerivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,799 F1 · kind: These shares of common stock were sold in a transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.06 to $5.29. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 7,101 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:13 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (right to buy) · Derivative | 202,427 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0000950170-25-034648 · ownership.xml · derivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,427 Underlying: Common Stock · 202,427 shares Expires 2035-03-03 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2025. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:24 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | SaleCommon Stock | 16,041 | $4.74 | $75,974.99 |
DisclosureSEC source: 0000950170-24-097071 · ownership.xml · nonDerivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,771 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $4.46 to $5.12. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 00:04 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | SaleCommon Stock | 11,537 | $3.16 | $36,503.07 |
DisclosureSEC source: 0000950170-24-030311 · ownership.xml · nonDerivative · entry 2 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,495 F3 · kind: These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2024 Filed Apr 17, 2024 20:12 UTC Amendment | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | SaleCommon Stock | 11,537 | $3.16 | $36,503.07 |
DisclosureSEC source: 0000950170-24-045113 · ownership.xml · nonDerivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,812 F1 · kind: These shares of common stock were sold by the Reporting Person for tax withholding and tax planning purposes in connection with the settlement of certain time-based restricted stock unit awards. This sale was previously reported in the Reporting Person's Form 4 filed on March 12, 2024 (the "Original Form 4"). F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.11 to $3.31. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Adjusted to reflect 9,317 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan, which were inadvertently omitted in the Original Form 4. The amount in Column 5 of this Form 4 reflects the number of shares beneficially owned by the Reporting Person as of the date of this report after giving effect to the adjustment. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 00:04 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | SaleCommon Stock | 18,231 | $3.41 | $62,102.08 |
DisclosureSEC source: 0000950170-24-030311 · ownership.xml · nonDerivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,032 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 09, 2024 Filed Mar 13, 2024 00:04 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (right to buy) · Derivative | 405,450 | $0.00 Strike: $3.62 | $0.00 |
DisclosureSEC source: 0000950170-24-030311 · ownership.xml · derivative · entry 4 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 405,450 Underlying: Common Stock · 405,450 shares Expires 2034-03-08 F6 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2024. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:27 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (right to buy) · Derivative | 220,258 | $0.00 Strike: $6.76 | $0.00 |
DisclosureSEC source: 0000899243-23-006748 · doc4.xml · derivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,258 Underlying: Common Stock · 220,258 shares Expires 2033-02-27 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2023. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:34 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantBonus Units · Derivative | 69,473 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026344 · doc4.xml · derivative · entry 3 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,473 Underlying: Common Stock · 69,473 shares Expires not disclosed F3 · derivative.exercise_price: Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. F3 · derivative.exercise_date: Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. F3 · derivative.expiration_date: Subject to and conditioned upon the acceptance by the U.S. Food and Drug Administration of the Issuer's submission of a New Drug Application for reproxalap, the bonus units vest ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The Reporting Person will be entitled to receive a cash payment for each vested bonus unit, on the earlier of (i) four (4) years from the date of grant or (ii) a Change of Control of the Issuer (as defined in the grant documents), equal in value to the closing price per share of the Company's common stock on The Nasdaq Capital Market on the payment date. Read SEC document |
| July 15, 2022 Filed Jul 19, 2022 20:34 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 185,605 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-026344 · doc4.xml · nonDerivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,263 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on July 15, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 23:37 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0000899243-22-013173 · doc4.xml · derivative · entry 3 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-03-29 F4 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 23:37 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 64,395 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013173 · doc4.xml · nonDerivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,658 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · balance_after: Includes 2,972 shares previously purchased under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 23:24 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 116,201 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0000899243-21-015838 · doc4.xml · derivative · entry 1 Machatha Stephen · CIK 0001836354 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,201 Underlying: Common Stock · 116,201 shares Expires 2031-04-11 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.